Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19
Through its new“Better Farms, Better Lives” initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting up to two million smallholder farmers facing increased challenges as a result of the on-going COVID-19 pandemic (Source: Bayer Company News)
Source: Bayer Company News - June 17, 2020 Category: Pharmaceuticals Source Type: news
Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction (for specialized target groups only)
FINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient population (Source: Bayer Company News)
Source: Bayer Company News - June 15, 2020 Category: Pharmaceuticals Source Type: news
Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure (for specialized target groups only)
Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1) (Source: Bayer Company News)
Source: Bayer Company News - June 5, 2020 Category: Pharmaceuticals Source Type: news
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - May 22, 2020 Category: Pharmaceuticals Source Type: news
Independent external council to advise Bayer ’ s Board of Management on consistent implementation of its sustainability targets
(Source: Bayer Company News)
Source: Bayer Company News - May 19, 2020 Category: Pharmaceuticals Source Type: news
Nubeqa ™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer (for specialized target groups only)
Darolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyle / ARAMIS data will be presented at the American Society of Clinical Oncology (ASCO)...
Source: Bayer Company News - May 13, 2020 Category: Pharmaceuticals Source Type: news
“ We ’ re active in the right businesses ”
Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders’ meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairman (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2020 Category: Pharmaceuticals Source Type: news
Bayer: Good start to 2020 – activities marked by COVID-19
Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx& portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings– strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiable (Source: Bayer Company News)
Source: Bayer Company News - April 27, 2020 Category: Pharmaceuticals Source Type: news
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patients (Source: Bayer Company News)
Source: Bayer Company News - April 21, 2020 Category: Pharmaceuticals Source Type: news
Bayer donates 8 million chloroquine tablets to the German Federal Government
Additional donations of chloroquine sent to governments in numerous other countries / Various clinical and preclinical studies investigate the efficacy and adverse effects in COVID-19 infections / Bayer plans considerable expansion of production capacities in the event that the efficacy of chloroquine is proven for COVID-19 (Source: Bayer Company News)
Source: Bayer Company News - April 14, 2020 Category: Pharmaceuticals Source Type: news
Bayer launches pre-filled syringe to administer eye medication Eylea ™ in Europe (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - April 8, 2020 Category: Pharmaceuticals Source Type: news
Bayer launches pre-filled syringe to administer eye medication Eylea ® in Europe (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - April 8, 2020 Category: Pharmaceuticals Source Type: news
Nubeqa ™ (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile (Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news
Nubeqa ® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Oral androgen receptor inhibitor (ARi) Nubeqa ® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free surviv al (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile (Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news
Bayer to boost Germany ’ s COVID-19 analysis capacity by several thousand tests per day
(Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news
